Valtecne (VLT) Q2 2024 TU earnings summary

Executive summary

• First half 2024 revenues reached €17.1 million, up 0.3% year-over-year, reflecting stable overall performance.

• Medical segment revenues grew 15.7% year-over-year, now accounting for 68.3% of total sales.

• Industrial segment revenues declined 21.9% year-over-year, impacted by weak Eurozone manufacturing conditions.

• Strategic focus on medical sector reinforced through commercial initiatives and participation in MedTecLIVE.

Financial highlights

• Total revenues for H1 2024: €17.1 million, compared to €17.0 million in H1 2023.

• Medical segment: €11.7 million (68.3% of total), up from €10.1 million (59.3%) in H1 2023.

• Industrial segment: €5.4 million (31.7% of total), down from €6.9 million (40.7%) in H1 2023.

Outlook and guidance

• 2024 viewed as a pivotal year for sustainable and lasting growth, with continued emphasis on the expanding medical market.